Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate | EJNMMI Research | Full Text
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine -
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies - Journal of Thoracic Oncology
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models - ScienceDirect
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody- drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer -
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study | Journal of Clinical Oncology
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
Pharmacokinetic head-to-head comparison between... | Download Scientific Diagram
Mirvetuximab Soravtansine - CancerConnect
Antibody drug conjugate: the “biological missile” for targeted cancer therapy | Signal Transduction and Targeted Therapy
Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer | Clearity Foundation
Sutro Biopharma: Revenue-Generating Platform Positioned For Growth (NASDAQ:STRO) | Seeking Alpha
PDF) Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models
Targeting the folate receptor for the treatment of ovarian cancer - Lutz - Translational Cancer Research
SORAVTANSINE
ImmunoGen Announces Accelerated Approval Pathway for Mirvetuximab Soravtansine in Ovarian Cancer | Business Wire
Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. - Abstract - Europe PMC
Unlocking the potential of antibody–drug conjugates for cancer therapy | Nature Reviews Clinical Oncology
Pharmaceuticals | Free Full-Text | Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications | HTML
On ImmunoGen and Mirvetuximab Soravtansine (IMGN 853), A Subjective Meta-Analysis From A Clinical Trial Based Perspective | PDF | Ovarian Cancer | Chemotherapy
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I - Annals of Oncology
